I could see a cash + script offer from Acadia as being potentially very attractive. It must be at least an option with the manner in which Acadia appear to be progressing.
With 100% ownership of 2591, it would form a huge part of their potential value, just as it now does with Neuren, but that value may be more truely assessed in the hands of an American biotech.
I would not be averse to a virtual transfer of my holdings to Acadia should a reasonable offer be made. They have done amazingly well with the Daybue commercialisation. In the hands of a major biotech 2591 would likely remain small fish in the overall picture for some time yet.
I am hoping for a satisfactory offer from them. We would likely no longer have to put up with the blatant manipulation we have been subjected to and which will likely continue for as long as we are 'going it alone'.
2591 has the potential to become a blockbuster and I would love an ongoing interest in it, with a company in which it was the major value driver. Acadia could be that company.
NEU Price at posting:
$13.27 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)